Table 2 MRD by MPFC studies including... | American Society of Hematology

Table 2

MRD by MPFC studies including more than 50 patients

Reference	No. of patients	Time point	Threshold postinduction, %	Threshold postconsolidation, %	Method	Multivariate analysis	Survival parameter
San Miguel⁷⁷	53	I, C	0.5	0.2	NA	I,C	RFS
Venditti⁸⁷	56	I, C	0.045	0.035	empirical	C	OS, RFS
San Miguel⁷⁸	126	I	< 0.01 0.01-0.1, 0.1-1, > 1	NA	NA	I	RFS
Kern⁷⁰	62	I, C	Continuous analysis log-difference	Continuous analysis log-difference	75th percentiles of log difference	C	RFS
Kern⁷¹	106	Day 16 after start of induction	Continuous analysis log-difference	NA	Median of log difference	Day 16 after start of induction	EFS, RFS
Buccisano⁷²	100	I, C	0.035	0.035	Maximally selected log-rank statistic	C	OS, RFS
Maurillo⁷³	142	I, C	0.035	0.035	Maximally selected log-rank statistic	C	OS, RFS
Al Mawali⁷⁵	54	I	0.15	0.15	ROC analysis	I	RFS, OS

Reference	No. of patients	Time point	Threshold postinduction, %	Threshold postconsolidation, %	Method	Multivariate analysis	Survival parameter
San Miguel⁷⁷	53	I, C	0.5	0.2	NA	I,C	RFS
Venditti⁸⁷	56	I, C	0.045	0.035	empirical	C	OS, RFS
San Miguel⁷⁸	126	I	< 0.01 0.01-0.1, 0.1-1, > 1	NA	NA	I	RFS
Kern⁷⁰	62	I, C	Continuous analysis log-difference	Continuous analysis log-difference	75th percentiles of log difference	C	RFS
Kern⁷¹	106	Day 16 after start of induction	Continuous analysis log-difference	NA	Median of log difference	Day 16 after start of induction	EFS, RFS
Buccisano⁷²	100	I, C	0.035	0.035	Maximally selected log-rank statistic	C	OS, RFS
Maurillo⁷³	142	I, C	0.035	0.035	Maximally selected log-rank statistic	C	OS, RFS
Al Mawali⁷⁵	54	I	0.15	0.15	ROC analysis	I	RFS, OS

I indicates induction; C, consolidation; NA, not available; EFS, event-free survival; and ROC, receiver operating characteristic.